Advertisement

Topics

Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress

09:02 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that additional data from its ongoing Phase 2 clinical trial of KD025 in chronic graft-versus-host disease (cGVHD) will be highlighted in an oral presentation at the 23rd Congres...

Other Sources for this Article

Investor Relations
Kadmon Holdings, Inc.
Ellen Tremaine, 646-490-2989
ellen.tremaine@kadmon.com

NEXT ARTICLE

More From BioPortfolio on "Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...